Valneva (VALN) announced that the European Commission has granted marketing authorization in Europe for Valneva’s single-dose vaccine, Ixchiq, for the prevention of disease caused by the chikungunya virus in individuals 12 years of age and older. The label extension complements the adult marketing authorization in Europe Valneva received in July 2024, the company said in a statement With this approval, Ixchiq becomes available in the market for adolescents in the EU, Norway, Liechtenstein and Iceland.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Valneva’s Strategic Advancements and Promising Projections Drive Buy Rating with $17 Target
- Valneva Seeks UK Approval for Adolescent Use of Chikungunya Vaccine
- Valneva renews sales agreement in connection with existing at-the-market program
- Valneva to provide 40,000 IXCHIQ doses in France starting early April
- Valneva files prospectus for sale of up to $350M shares
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue